EGFRm+ NSCLC with de novo MET amplification, an uncommon but clinically relevant molecular configuration, also deserves special diagnostic awareness and therapeutic consideration, as combined EGFR-TKI/MET-TKI treatment will be needed up-front in this setting. This evidence concerns the gene MET and non-small cell lung carcinoma.